{"entity":{"type":"insider","cik":"0001778307","url":"/insider/0001778307","json_url":"/insider/0001778307.json","name":"Cheng Andrew","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":101,"n_filings":47,"first":"2021-07-06","last":"2025-10-14","span_basis":"filed_date"},"name_variants":[{"name":"Cheng Andrew","source":"filing","n_filings":47,"first_seen":"2021-07-06","last_seen":"2025-10-14"}],"transactions":[{"id":4879806,"accession":"0001193125-25-239343","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-239343","line_url":"/filing/0001193125-25-239343#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":53.978,"price_display":"53.98","price_state":"stated","total_value":1619340.0,"total_display":"1,619,340.00","shares_owned_after":526114.0,"shares_owned_after_display":"526,114","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-10","filed_date":"2025-10-14","scope":"insider"},{"id":4264932,"accession":"0000950170-25-114661","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-25-114661","line_url":"/filing/0000950170-25-114661#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1796.0,"shares_display":"1,796","price_per_share":43.02,"price_display":"43.02","price_state":"stated","total_value":77263.92,"total_display":"77,263.92","shares_owned_after":473902.0,"shares_owned_after_display":"473,902","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-12","scope":"insider"},{"id":4264930,"accession":"0000950170-25-114661","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-25-114661","line_url":"/filing/0000950170-25-114661#line-5","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22525.0,"shares_display":"22,525","price_per_share":42.994,"price_display":"42.99","price_state":"stated","total_value":968439.85,"total_display":"968,439.85","shares_owned_after":483173.0,"shares_owned_after_display":"483,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-10","filed_date":"2025-09-12","scope":"insider"},{"id":4264929,"accession":"0000950170-25-114661","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-114661","line_url":"/filing/0000950170-25-114661#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7317.0,"shares_display":"7,317","price_per_share":43.995,"price_display":"44.00","price_state":"stated","total_value":321911.415,"total_display":"321,911.42","shares_owned_after":475856.0,"shares_owned_after_display":"475,856","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-10","filed_date":"2025-09-12","scope":"insider"},{"id":4264927,"accession":"0000950170-25-114661","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-114661","line_url":"/filing/0000950170-25-114661#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":158.0,"shares_display":"158","price_per_share":44.62,"price_display":"44.62","price_state":"stated","total_value":7049.96,"total_display":"7,049.96","shares_owned_after":475698.0,"shares_owned_after_display":"475,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-10","filed_date":"2025-09-12","scope":"insider"},{"id":4751542,"accession":"0000950170-25-108232","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-108232","line_url":"/filing/0000950170-25-108232#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18805.0,"shares_display":"18,805","price_per_share":48.865,"price_display":"48.86","price_state":"stated","total_value":918906.325,"total_display":"918,906.32","shares_owned_after":491157.0,"shares_owned_after_display":"491,157","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-11","filed_date":"2025-08-13","scope":"insider"},{"id":4751538,"accession":"0000950170-25-108232","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-108232","line_url":"/filing/0000950170-25-108232#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10795.0,"shares_display":"10,795","price_per_share":48.07,"price_display":"48.07","price_state":"stated","total_value":518915.65,"total_display":"518,915.65","shares_owned_after":509962.0,"shares_owned_after_display":"509,962","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-11","filed_date":"2025-08-13","scope":"insider"},{"id":4751534,"accession":"0000950170-25-108232","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-108232","line_url":"/filing/0000950170-25-108232#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":49.435,"price_display":"49.44","price_state":"stated","total_value":19774.0,"total_display":"19,774.00","shares_owned_after":490757.0,"shares_owned_after_display":"490,757","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-11","filed_date":"2025-08-13","scope":"insider"},{"id":4462916,"accession":"0000950170-25-095409","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-095409","line_url":"/filing/0000950170-25-095409#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15314.0,"shares_display":"15,314","price_per_share":51.732,"price_display":"51.73","price_state":"stated","total_value":792223.848,"total_display":"792,223.85","shares_owned_after":520757.0,"shares_owned_after_display":"520,757","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-10","filed_date":"2025-07-11","scope":"insider"},{"id":4462910,"accession":"0000950170-25-095409","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-095409","line_url":"/filing/0000950170-25-095409#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14686.0,"shares_display":"14,686","price_per_share":50.57,"price_display":"50.57","price_state":"stated","total_value":742671.02,"total_display":"742,671.02","shares_owned_after":536071.0,"shares_owned_after_display":"536,071","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-10","filed_date":"2025-07-11","scope":"insider"},{"id":4983141,"accession":"0000950170-25-088641","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-088641","line_url":"/filing/0000950170-25-088641#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6620.0,"shares_display":"6,620","price_per_share":54.84,"price_display":"54.84","price_state":"stated","total_value":363040.8,"total_display":"363,040.80","shares_owned_after":549867.0,"shares_owned_after_display":"549,867","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-18","filed_date":"2025-06-20","scope":"insider"},{"id":4661954,"accession":"0000950170-25-085674","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-085674","line_url":"/filing/0000950170-25-085674#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15158.0,"shares_display":"15,158","price_per_share":54.353,"price_display":"54.35","price_state":"stated","total_value":823882.774,"total_display":"823,882.77","shares_owned_after":564324.0,"shares_owned_after_display":"564,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":4661950,"accession":"0000950170-25-085674","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-085674","line_url":"/filing/0000950170-25-085674#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14842.0,"shares_display":"14,842","price_per_share":53.76,"price_display":"53.76","price_state":"stated","total_value":797905.92,"total_display":"797,905.92","shares_owned_after":579482.0,"shares_owned_after_display":"579,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":4661946,"accession":"0000950170-25-085674","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-085674","line_url":"/filing/0000950170-25-085674#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7837.0,"shares_display":"7,837","price_per_share":53.994,"price_display":"53.99","price_state":"stated","total_value":423150.978,"total_display":"423,150.98","shares_owned_after":556487.0,"shares_owned_after_display":"556,487","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":4791969,"accession":"0000950170-25-070811","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-070811","line_url":"/filing/0000950170-25-070811#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22800.0,"shares_display":"22,800","price_per_share":41.634,"price_display":"41.63","price_state":"stated","total_value":949255.2,"total_display":"949,255.20","shares_owned_after":594324.0,"shares_owned_after_display":"594,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-12","filed_date":"2025-05-13","scope":"insider"},{"id":4791965,"accession":"0000950170-25-070811","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-070811","line_url":"/filing/0000950170-25-070811#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7200.0,"shares_display":"7,200","price_per_share":41.0,"price_display":"41.00","price_state":"stated","total_value":295200.0,"total_display":"295,200.00","shares_owned_after":617124.0,"shares_owned_after_display":"617,124","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-12","filed_date":"2025-05-13","scope":"insider"},{"id":4164971,"accession":"0000950170-25-053391","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-053391","line_url":"/filing/0000950170-25-053391#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":35.226,"price_display":"35.23","price_state":"stated","total_value":1056780.0,"total_display":"1,056,780.00","shares_owned_after":624324.0,"shares_owned_after_display":"624,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-10","filed_date":"2025-04-11","scope":"insider"},{"id":4194463,"accession":"0000950170-25-039765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-039765","line_url":"/filing/0000950170-25-039765#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1738.0,"shares_display":"1,738","price_per_share":44.88,"price_display":"44.88","price_state":"stated","total_value":78001.44,"total_display":"78,001.44","shares_owned_after":654324.0,"shares_owned_after_display":"654,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-12","filed_date":"2025-03-14","scope":"insider"},{"id":4340725,"accession":"0000950170-25-038177","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-038177","line_url":"/filing/0000950170-25-038177#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28784.0,"shares_display":"28,784","price_per_share":41.746,"price_display":"41.75","price_state":"stated","total_value":1201616.864,"total_display":"1,201,616.86","shares_owned_after":657278.0,"shares_owned_after_display":"657,278","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-10","filed_date":"2025-03-12","scope":"insider"},{"id":4340722,"accession":"0000950170-25-038177","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-038177","line_url":"/filing/0000950170-25-038177#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1216.0,"shares_display":"1,216","price_per_share":42.313,"price_display":"42.31","price_state":"stated","total_value":51452.608,"total_display":"51,452.61","shares_owned_after":656062.0,"shares_owned_after_display":"656,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-10","filed_date":"2025-03-12","scope":"insider"},{"id":4311613,"accession":"0000950170-25-018311","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-25-018311","line_url":"/filing/0000950170-25-018311#line-5","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12640.0,"shares_display":"12,640","price_per_share":51.752,"price_display":"51.75","price_state":"stated","total_value":654145.28,"total_display":"654,145.28","shares_owned_after":703422.0,"shares_owned_after_display":"703,422","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-11","scope":"insider"},{"id":4311609,"accession":"0000950170-25-018311","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-018311","line_url":"/filing/0000950170-25-018311#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9972.0,"shares_display":"9,972","price_per_share":53.666,"price_display":"53.67","price_state":"stated","total_value":535157.352,"total_display":"535,157.35","shares_owned_after":687011.0,"shares_owned_after_display":"687,011","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-11","scope":"insider"},{"id":4311606,"accession":"0000950170-25-018311","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-018311","line_url":"/filing/0000950170-25-018311#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6439.0,"shares_display":"6,439","price_per_share":52.908,"price_display":"52.91","price_state":"stated","total_value":340674.612,"total_display":"340,674.61","shares_owned_after":696983.0,"shares_owned_after_display":"696,983","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-11","scope":"insider"},{"id":4311602,"accession":"0000950170-25-018311","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-018311","line_url":"/filing/0000950170-25-018311#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":749.0,"shares_display":"749","price_per_share":54.546,"price_display":"54.55","price_state":"stated","total_value":40854.954,"total_display":"40,854.95","shares_owned_after":686262.0,"shares_owned_after_display":"686,262","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-11","scope":"insider"},{"id":4311597,"accession":"0000950170-25-018311","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-018311","line_url":"/filing/0000950170-25-018311#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":55.81,"price_display":"55.81","price_state":"stated","total_value":11162.0,"total_display":"11,162.00","shares_owned_after":686062.0,"shares_owned_after_display":"686,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-11","scope":"insider"},{"id":4790161,"accession":"0000950170-25-010705","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-010705","line_url":"/filing/0000950170-25-010705#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24242.0,"shares_display":"24,242","price_per_share":54.56,"price_display":"54.56","price_state":"stated","total_value":1322643.52,"total_display":"1,322,643.52","shares_owned_after":721820.0,"shares_owned_after_display":"721,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-29","scope":"insider"},{"id":4790157,"accession":"0000950170-25-010705","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-010705","line_url":"/filing/0000950170-25-010705#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3377.0,"shares_display":"3,377","price_per_share":56.89,"price_display":"56.89","price_state":"stated","total_value":192117.53,"total_display":"192,117.53","shares_owned_after":716062.0,"shares_owned_after_display":"716,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-29","scope":"insider"},{"id":4790153,"accession":"0000950170-25-010705","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-010705","line_url":"/filing/0000950170-25-010705#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2381.0,"shares_display":"2,381","price_per_share":55.53,"price_display":"55.53","price_state":"stated","total_value":132216.93,"total_display":"132,216.93","shares_owned_after":719439.0,"shares_owned_after_display":"719,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-29","scope":"insider"},{"id":2834056,"accession":"0000950170-24-136017","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-136017","line_url":"/filing/0000950170-24-136017#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7855.0,"shares_display":"7,855","price_per_share":30.79,"price_display":"30.79","price_state":"stated","total_value":241855.45,"total_display":"241,855.45","shares_owned_after":597562.0,"shares_owned_after_display":"597,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider"},{"id":3265014,"accession":"0000950170-24-133435","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-133435","line_url":"/filing/0000950170-24-133435#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":32.09,"price_display":"32.09","price_state":"stated","total_value":802250.0,"total_display":"802,250.00","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-02","filed_date":"2024-12-04","scope":"insider"},{"id":2773373,"accession":"0000950170-24-121100","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-121100","line_url":"/filing/0000950170-24-121100#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":81280.0,"shares_display":"81,280","price_per_share":31.472,"price_display":"31.47","price_state":"stated","total_value":2558044.16,"total_display":"2,558,044.16","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-01","filed_date":"2024-11-05","scope":"insider"},{"id":2773364,"accession":"0000950170-24-121100","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-121100","line_url":"/filing/0000950170-24-121100#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27086.0,"shares_display":"27,086","price_per_share":32.499,"price_display":"32.50","price_state":"stated","total_value":880267.914,"total_display":"880,267.91","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-01","filed_date":"2024-11-05","scope":"insider"},{"id":2902963,"accession":"0000950170-24-115731","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000950170-24-115731","line_url":"/filing/0000950170-24-115731#line-7","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63313.0,"shares_display":"63,313","price_per_share":31.527,"price_display":"31.53","price_state":"stated","total_value":1996068.951,"total_display":"1,996,068.95","shares_owned_after":605643.0,"shares_owned_after_display":"605,643","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-18","filed_date":"2024-10-18","scope":"insider"},{"id":2902961,"accession":"0000950170-24-115731","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-115731","line_url":"/filing/0000950170-24-115731#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":226.0,"shares_display":"226","price_per_share":32.12,"price_display":"32.12","price_state":"stated","total_value":7259.12,"total_display":"7,259.12","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-18","filed_date":"2024-10-18","scope":"insider"},{"id":2902954,"accession":"0000950170-24-115731","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-115731","line_url":"/filing/0000950170-24-115731#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3103.0,"shares_display":"3,103","price_per_share":31.118,"price_display":"31.12","price_state":"stated","total_value":96559.154,"total_display":"96,559.15","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-17","filed_date":"2024-10-18","scope":"insider"},{"id":2902947,"accession":"0000950170-24-115731","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-115731","line_url":"/filing/0000950170-24-115731#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24992.0,"shares_display":"24,992","price_per_share":31.136,"price_display":"31.14","price_state":"stated","total_value":778150.912,"total_display":"778,150.91","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-16","filed_date":"2024-10-18","scope":"insider"},{"id":2772662,"accession":"0000950170-24-106451","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-106451","line_url":"/filing/0000950170-24-106451#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1738.0,"shares_display":"1,738","price_per_share":26.18,"price_display":"26.18","price_state":"stated","total_value":45500.84,"total_display":"45,500.84","shares_owned_after":605417.0,"shares_owned_after_display":"605,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-13","scope":"insider"},{"id":2460886,"accession":"0000950170-24-073181","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-073181","line_url":"/filing/0000950170-24-073181#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7894.0,"shares_display":"7,894","price_per_share":22.641,"price_display":"22.64","price_state":"stated","total_value":178728.054,"total_display":"178,728.05","shares_owned_after":581553.0,"shares_owned_after_display":"581,553","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-11","filed_date":"2024-06-13","scope":"insider"},{"id":2893871,"accession":"0000950170-24-032263","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-032263","line_url":"/filing/0000950170-24-032263#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1969.0,"shares_display":"1,969","price_per_share":28.33,"price_display":"28.33","price_state":"stated","total_value":55781.77,"total_display":"55,781.77","shares_owned_after":589447.0,"shares_owned_after_display":"589,447","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-15","scope":"insider"},{"id":2587111,"accession":"0000950170-24-027510","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000950170-24-027510","line_url":"/filing/0000950170-24-027510#line-8","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35827.0,"shares_display":"35,827","price_per_share":31.4002,"price_display":"31.40","price_state":"stated","total_value":1124974.9654,"total_display":"1,124,974.97","shares_owned_after":630589.0,"shares_owned_after_display":"630,589","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":2587107,"accession":"0000950170-24-027510","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000950170-24-027510","line_url":"/filing/0000950170-24-027510#line-7","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14680.0,"shares_display":"14,680","price_per_share":34.6303,"price_display":"34.63","price_state":"stated","total_value":508372.804,"total_display":"508,372.80","shares_owned_after":599525.0,"shares_owned_after_display":"599,525","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":2587101,"accession":"0000950170-24-027510","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-027510","line_url":"/filing/0000950170-24-027510#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9614.0,"shares_display":"9,614","price_per_share":33.8326,"price_display":"33.83","price_state":"stated","total_value":325266.6164,"total_display":"325,266.62","shares_owned_after":614205.0,"shares_owned_after_display":"614,205","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":2587098,"accession":"0000950170-24-027510","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-027510","line_url":"/filing/0000950170-24-027510#line-5","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7995.0,"shares_display":"7,995","price_per_share":35.4941,"price_display":"35.49","price_state":"stated","total_value":283775.3295,"total_display":"283,775.33","shares_owned_after":591530.0,"shares_owned_after_display":"591,530","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":2587088,"accession":"0000950170-24-027510","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-027510","line_url":"/filing/0000950170-24-027510#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6770.0,"shares_display":"6,770","price_per_share":32.2803,"price_display":"32.28","price_state":"stated","total_value":218537.631,"total_display":"218,537.63","shares_owned_after":623819.0,"shares_owned_after_display":"623,819","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":2587081,"accession":"0000950170-24-027510","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-027510","line_url":"/filing/0000950170-24-027510#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114.0,"shares_display":"114","price_per_share":36.28,"price_display":"36.28","price_state":"stated","total_value":4135.92,"total_display":"4,135.92","shares_owned_after":591416.0,"shares_owned_after_display":"591,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":8217000,"accession":"0000950170-23-071242","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-071242","line_url":"/filing/0000950170-23-071242#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1628.0,"shares_display":"1,628","price_per_share":20.76,"price_display":"20.76","price_state":"stated","total_value":33797.28,"total_display":"33,797.28","shares_owned_after":550911.0,"shares_owned_after_display":"550,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-14","filed_date":"2023-12-18","scope":"insider"},{"id":8012220,"accession":"0000950170-23-069504","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000950170-23-069504","line_url":"/filing/0000950170-23-069504#line-7","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7405.0,"shares_display":"7,405","price_per_share":20.0233,"price_display":"20.02","price_state":"stated","total_value":148272.5365,"total_display":"148,272.54","shares_owned_after":552539.0,"shares_owned_after_display":"552,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-11","filed_date":"2023-12-11","scope":"insider"},{"id":8012213,"accession":"0000950170-23-069504","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-23-069504","line_url":"/filing/0000950170-23-069504#line-5","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12873.0,"shares_display":"12,873","price_per_share":20.0086,"price_display":"20.01","price_state":"stated","total_value":257570.7078,"total_display":"257,570.71","shares_owned_after":460998.0,"shares_owned_after_display":"460,998","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-08","filed_date":"2023-12-11","scope":"insider"},{"id":8012206,"accession":"0000950170-23-069504","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-069504","line_url":"/filing/0000950170-23-069504#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6700.0,"shares_display":"6,700","price_per_share":20.0187,"price_display":"20.02","price_state":"stated","total_value":134125.29,"total_display":"134,125.29","shares_owned_after":460998.0,"shares_owned_after_display":"460,998","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-07","filed_date":"2023-12-11","scope":"insider"},{"id":8108602,"accession":"0000950170-23-052057","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-23-052057","line_url":"/filing/0000950170-23-052057#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001778307","owner_name":"Cheng Andrew","owner_url":"/insider/0001778307","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8868.0,"shares_display":"8,868","price_per_share":46.057,"price_display":"46.06","price_state":"stated","total_value":408433.476,"total_display":"408,433.48","shares_owned_after":477130.0,"shares_owned_after_display":"477,130","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-02","filed_date":"2023-10-04","scope":"insider"}],"next_cursor":"2023-10-02|8108602","ledger_fault":false,"count":{"value":101,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":101,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":101},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Director, Officer (President and CEO)","n_filings":47,"first_seen":"2021-07-06","last_seen":"2025-10-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001778307","retrieved_at":"2026-08-21T16:58:32+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}